Our regular patent and pharma update aims to keep you informed of recent developments in United Kingdom and European law relating to patents and the pharmaceutical industry.
- Regeneron's transgenic mice patents held invalid for insufficiency by English Patents Court
Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor [2016] EWHC 87 (Pat), 1 February 2016. Read more
- English Patents Court grants Actavis pan-European declarations of non-infringement for its lung cancer treatment
Actavis UK Ltd & Ors v Eli Lilly & Co (Rev 1) [2016] EWHC 234 (Pat), 12 February 2016. Read more
- English Patents Court refuses Janssen's application to stay proceedings pending EPO opposition decision
Eli Lilly And Co. v Janssen Sciences Ireland UC [2016] EWHC 313 (Pat), 18 February 2016. Read more
- Medac's methotrexate formulation patent found invalid by the English Patents Court
Accord Healthcare Ltd v medac Gesellschaft Für Klinische Spezialpräparate Mbh [2016] EWHC 24 (Pat), 13 January 2016. Read more
- English Court of Appeal declares patent obvious by considering information "the skilled person would ask" Richter Gedeon Vegyeszeti Gyar RT v Generics (UK) Ltd (t/a) Mylan [2016] EWCA Civ 410, 26 April 2016. Read more
- Grant of MA with post-authorisation conditions can define the start of the 10 year data exclusivity period Accord Healthcare Ltd & Anor v Astellas Pharma GmbH & Anor [2015] EWHC 3676 (Ch), 16 December 2015. Read more
- American Science & Engineering's mobile X-ray backscatter inspection system patent held valid by the English Patents Court
American Science & Engineering Inc v Rapiscan Systems Ltd [2016] EWHC 756 (Pat), 11 April 2016. Read more
- GSK and generics fined £45 million for anti-competitive 'pay-for-delay' agreements
Final infringement decision, Paroxetine investigation: anti-competitive agreements and conduct, Case reference: CE/9531-11, UK Competition and Markets Authority, 12 February 2016. Read more
Click here for a summary table of key points from featured decisions related to patents.
Click here for a summary table of key points from featured decisions on issues other than patents.
Contact
Jonathan Turnbull
Partner, London
Disclaimer
The articles published on this website, current at the dates of publication set out above, are for reference purposes only. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action.